These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 30168265)
1. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France). Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265 [TBL] [Abstract][Full Text] [Related]
2. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience. Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727 [TBL] [Abstract][Full Text] [Related]
3. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133 [TBL] [Abstract][Full Text] [Related]
4. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048 [TBL] [Abstract][Full Text] [Related]
5. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis. Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519 [TBL] [Abstract][Full Text] [Related]
6. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562 [TBL] [Abstract][Full Text] [Related]
7. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789 [TBL] [Abstract][Full Text] [Related]
8. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study. Einarsson JT; Geborek P; Saxne T; Kapetanovic MC J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762 [TBL] [Abstract][Full Text] [Related]
9. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers. Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942 [TBL] [Abstract][Full Text] [Related]
10. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846 [TBL] [Abstract][Full Text] [Related]
11. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402 [TBL] [Abstract][Full Text] [Related]
12. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659 [TBL] [Abstract][Full Text] [Related]
13. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600 [TBL] [Abstract][Full Text] [Related]
15. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis. Mori A; Saito T; Takahashi M; Shibata M; Tsuji G; Hatachi S; Takahashi S; Kumagai S PLoS One; 2020; 15(12):e0243729. PubMed ID: 33315881 [TBL] [Abstract][Full Text] [Related]
16. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V; Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594 [TBL] [Abstract][Full Text] [Related]
17. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis. García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336 [TBL] [Abstract][Full Text] [Related]